TapewireFind a company

person · Reporting owner

Cooke Julie

Disclosed activity across 1 company

Tapewire entity
41470
SEC CIK
0001776977

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655Chief Human Resources OfficerSeptember 11, 2026September 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

NEUROCRINE BIOSCIENCES INC

Report date September 11, 2026 · Filed September 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect25,961 Reported balance After 2026-09-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-09-11 · Grant · Acquired 3,587 · Balance 25,961

F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

Common StockSEC Table I · non-derivativeDirect24,025 Reported balance After 2026-09-11 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2026-09-11 · Tax withholding · Disposed 1,936 · Balance 24,025

F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

F3: 21,985 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

F3: 21,985 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 01, 2024 Filed Jul 3, 2024 01:36 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 10,000 $61.82 $618,200.00
Disclosure

SEC source: 0000914475-24-000166 · wk-form4_1719970585.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,202

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes an aggregate of 226 shares purchased on February 29, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:35 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantRestricted Stock Unit · Derivative 5,604 $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000070 · wk-form4_1708036535.xml · derivative · entry 3

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,604

Underlying: Common Stock · 5,604 shares

Expires not disclosed

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:35 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantStock Option · Derivative 28,161 $0.00 Strike: $133.84 $0.00
Disclosure

SEC source: 0000914475-24-000070 · wk-form4_1708036535.xml · derivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,161

Underlying: Common Stock · 28,161 shares

Expires 2034-02-13

F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:35 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 796 $133.04 $105,902.15
Disclosure

SEC source: 0000914475-24-000070 · wk-form4_1708036535.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,976

F1 · kind: Sale of 796 shares of common stock issued upon vesting of 1,509 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (713) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: 15,825 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:35 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 629 $136.78 $86,034.62
Disclosure

SEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 4

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,263

F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F6 · balance_after: 15,825 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:35 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 700 $134.23 $93,960.86
Disclosure

SEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 3

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,892

F4 · kind: Sale of 700 shares of common stock issued upon vesting of 1,329 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (629) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 06, 2024 Filed Feb 9, 2024 00:35 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 575 $141.96 $81,627.00
Disclosure

SEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,263

F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
February 06, 2024 Filed Feb 9, 2024 00:35 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 640 $142.17 $90,989.76
Disclosure

SEC source: 0000914475-24-000050 · wk-form4_1707438893.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,838

F1 · kind: Sale of 640 shares of common stock issued upon vesting of 1,215 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (575) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.05 to $143.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 31, 2024 Filed Feb 3, 2024 00:11 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 824 $141.94 $116,958.56
Disclosure

SEC source: 0000914475-24-000025 · wk-form4_1706919106.xml · nonDerivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,263

F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · balance_after: 15,825 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.

Read SEC document
January 31, 2024 Filed Feb 3, 2024 00:11 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 916 $140.70 $128,882.94
Disclosure

SEC source: 0000914475-24-000025 · wk-form4_1706919106.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,087

F1 · kind: Sale of 916 shares of common stock issued upon vesting of 1,740 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (824) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.74 to $142.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
December 22, 2023 Filed Dec 27, 2023 21:08 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 10,000 $61.82 Strike: $61.82 $618,200.00
Disclosure

SEC source: 0001209191-23-059768 · doc4.xml · derivative · entry 6

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,532

Underlying: Common Stock · 10,000 shares

Expires 2027-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Option granted October 02, 2017 of which 1/4th of the shares underlying the option becomes vested and exercisable on October 02, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.

Read SEC document
December 22, 2023 Filed Dec 27, 2023 21:08 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 14,000 $81.05 Strike: $81.05 $1,134,700.00
Disclosure

SEC source: 0001209191-23-059768 · doc4.xml · derivative · entry 5

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,129

Underlying: Common Stock · 14,000 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Option granted February 07, 2019 and vested monthly over four years.

Read SEC document
December 22, 2023 Filed Dec 27, 2023 21:08 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 10,000 $126.79 $1,267,945.00
Disclosure

SEC source: 0001209191-23-059768 · doc4.xml · nonDerivative · entry 4

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,263

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $128.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · balance_after: 15,825 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.

Read SEC document
December 22, 2023 Filed Dec 27, 2023 21:08 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 10,000 $61.82 $618,200.00
Disclosure

SEC source: 0001209191-23-059768 · doc4.xml · nonDerivative · entry 3

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,263

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 22, 2023 Filed Dec 27, 2023 21:08 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 14,000 $129.99 $1,819,862.80
Disclosure

SEC source: 0001209191-23-059768 · doc4.xml · nonDerivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,263

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.95 to $130.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
December 22, 2023 Filed Dec 27, 2023 21:08 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 14,000 $81.05 $1,134,700.00
Disclosure

SEC source: 0001209191-23-059768 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,263

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 01, 2023 Filed Sep 6, 2023 20:22 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 824 $110.93 $91,406.32
Disclosure

SEC source: 0001209191-23-048381 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,263

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
August 21, 2023 Filed Aug 24, 2023 00:03 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 2,132 $107.41 $228,990.66
Disclosure

SEC source: 0001209191-23-047133 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,087

F1 · kind: Sale of 2,132 shares of common stock issued upon vesting of 4,050 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,918) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
May 01, 2023 Filed May 3, 2023 21:28 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 11,397 $103.89 $1,184,049.15
Disclosure

SEC source: 0001209191-23-027089 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,169

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.82 to $104.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
April 25, 2023 Filed Apr 27, 2023 20:37 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 100 $103.82 $10,382.00
Disclosure

SEC source: 0001209191-23-025862 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,561

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · balance_after: Includes an aggregate of 237 shares purchased on February 28, 2023 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

Read SEC document
February 13, 2023 Filed Feb 16, 2023 00:08 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantRestricted Stock Unit · Derivative 6,038 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-009883 · doc4.xml · derivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,038

Underlying: Common Stock · 6,038 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027.

F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027.

Read SEC document
February 13, 2023 Filed Feb 16, 2023 00:08 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantStock Option · Derivative 37,523 $0.00 Strike: $103.52 $0.00
Disclosure

SEC source: 0001209191-23-009883 · doc4.xml · derivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,523

Underlying: Common Stock · 37,523 shares

Expires 2033-02-13

F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 08, 2023 Filed Feb 9, 2023 00:56 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 628 $103.69 $65,117.32
Disclosure

SEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 7

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,424

F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
February 08, 2023 Filed Feb 9, 2023 00:56 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 700 $103.95 $72,765.98
Disclosure

SEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 6

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,052

F9 · kind: Sale of 700 shares of common stock issued upon vesting of 1,328 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (628) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F10 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.58 to $105.72. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 07, 2023 Filed Feb 9, 2023 00:56 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 822 $104.03 $85,512.66
Disclosure

SEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 5

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,424

F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
February 07, 2023 Filed Feb 9, 2023 00:56 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 12,801 $102.41 $1,310,915.85
Disclosure

SEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 4

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,246

F6 · kind: Sale of 12,801 shares of common stock issued upon vesting of 24,298 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (11,497) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan

F7 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023.

F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.03 to $103.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 07, 2023 Filed Feb 9, 2023 00:56 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 913 $102.25 $93,350.32
Disclosure

SEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 3

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,749

F4 · kind: Sale of 913 shares of common stock issued upon vesting of 1,736 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (823) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.87 to $103.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 06, 2023 Filed Feb 9, 2023 00:56 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 575 $104.28 $59,961.00
Disclosure

SEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,926

F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
February 06, 2023 Filed Feb 9, 2023 00:56 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 640 $105.47 $67,498.18
Disclosure

SEC source: 0001209191-23-007917 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,501

F1 · kind: Sale of 640 shares of common stock issued upon vesting of 1,215 restricted stock units on February 6, 2022 to cover payroll and withholding taxes, with the balance of the shares (575) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.05 to $106.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 22:07 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 916 $108.48 $99,367.68
Disclosure

SEC source: 0001209191-23-006267 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,926

F1 · kind: Sale of 916 shares of common stock issued upon vesting of 1,740 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (824) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
November 08, 2022 Filed Nov 10, 2022 22:47 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 5,592 $81.05 Strike: $81.05 $453,231.60
Disclosure

SEC source: 0001209191-22-056435 · doc4.xml · derivative · entry 3

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,129

Underlying: Common Stock · 5,592 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted February 07, 2019 and vested monthly over four years.

Read SEC document
November 08, 2022 Filed Nov 10, 2022 22:47 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 5,592 $124.99 $698,949.11
Disclosure

SEC source: 0001209191-22-056435 · doc4.xml · nonDerivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,102

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $124.95 to $125.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 08, 2022 Filed Nov 10, 2022 22:47 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 5,592 $81.05 $453,231.60
Disclosure

SEC source: 0001209191-22-056435 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,694

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 03, 2022 Filed Nov 4, 2022 21:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 7,264 $81.05 Strike: $81.05 $588,747.20
Disclosure

SEC source: 0001209191-22-055819 · doc4.xml · derivative · entry 6

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,721

Underlying: Common Stock · 7,264 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted February 07, 2019 and vested monthly over four years.

Read SEC document
November 03, 2022 Filed Nov 4, 2022 21:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 7,264 $125.00 $908,034.14
Disclosure

SEC source: 0001209191-22-055819 · doc4.xml · nonDerivative · entry 4

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,102

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $124.95 to $125.17. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 03, 2022 Filed Nov 4, 2022 21:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 7,264 $81.05 $588,747.20
Disclosure

SEC source: 0001209191-22-055819 · doc4.xml · nonDerivative · entry 3

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,366

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 02, 2022 Filed Nov 4, 2022 21:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 1,144 $81.05 Strike: $81.05 $92,721.20
Disclosure

SEC source: 0001209191-22-055819 · doc4.xml · derivative · entry 5

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,985

Underlying: Common Stock · 1,144 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted February 07, 2019 and vested monthly over four years.

Read SEC document
November 02, 2022 Filed Nov 4, 2022 21:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 1,144 $124.97 $142,962.82
Disclosure

SEC source: 0001209191-22-055819 · doc4.xml · nonDerivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,102

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $124.95 to $125.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 02, 2022 Filed Nov 4, 2022 21:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 1,144 $81.05 $92,721.20
Disclosure

SEC source: 0001209191-22-055819 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,246

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 05, 2022 Filed Aug 9, 2022 22:54 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 1,816 $100.00 $181,600.00
Disclosure

SEC source: 0001209191-22-045082 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,102

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
June 27, 2022 Filed Jun 29, 2022 20:26 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 754 $100.00 $75,400.00
Disclosure

SEC source: 0001209191-22-039808 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,918

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · balance_after: Includes an aggregate of 261 shares purchased on February 28, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

Read SEC document
February 08, 2022 Filed Feb 9, 2022 23:55 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 700 $79.56 $55,689.13
Disclosure

SEC source: 0001209191-22-008205 · doc4.xml · nonDerivative · entry 4

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,411

F7 · kind: Sale of 700 shares of common stock issued upon vesting of 1,328 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (628) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.10 to $79.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 07, 2022 Filed Feb 9, 2022 23:55 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 640 $80.63 $51,600.19
Disclosure

SEC source: 0001209191-22-008205 · doc4.xml · nonDerivative · entry 3

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,783

F5 · kind: Sale of 640 shares of common stock issued upon vesting of 1,215 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (575) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.76 to $81.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 07, 2022 Filed Feb 9, 2022 23:55 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 913 $80.73 $73,706.76
Disclosure

SEC source: 0001209191-22-008205 · doc4.xml · nonDerivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,208

F3 · kind: Sale of 913 shares of common stock issued upon vesting of 1,735 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (822) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.79 to $81.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 07, 2022 Filed Feb 9, 2022 23:55 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 605 $80.55 $48,731.24
Disclosure

SEC source: 0001209191-22-008205 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,386

F1 · kind: Sale of 605 shares of common stock issued upon vesting of 1,150 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (545) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.78 to $81.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 31, 2022 Filed Feb 3, 2022 01:06 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantRestricted Stock Unit · Derivative 6,961 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-006592 · doc4.xml · derivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,961

Underlying: Common Stock · 6,961 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026.

F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026.

Read SEC document
January 31, 2022 Filed Feb 3, 2022 01:06 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantStock Option · Derivative 47,401 $0.00 Strike: $79.02 $0.00
Disclosure

SEC source: 0001209191-22-006592 · doc4.xml · derivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,401

Underlying: Common Stock · 47,401 shares

Expires 2032-01-31

F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
October 04, 2021 Filed Oct 6, 2021 20:37 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 987 $101.73 $100,407.51
Disclosure

SEC source: 0001209191-21-059839 · doc4.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,841

F1 · kind: Sale of 987 shares of common stock issued upon vesting of 1,875 restricted stock units on October 4, 2021 to cover payroll and withholding taxes, with the balance of the shares (888) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · balance_after: Includes 216 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 26, 2021.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 02:24 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantRestricted Stock Unit · Derivative 5,314 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-009125 · doc4.xml · derivative · entry 5

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,314

Underlying: Common Stock · 5,314 shares

Expires not disclosed

F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025.

F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 02:24 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantStock Option · Derivative 31,880 $0.00 Strike: $117.63 $0.00
Disclosure

SEC source: 0001209191-21-009125 · doc4.xml · derivative · entry 4

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,880

Underlying: Common Stock · 31,880 shares

Expires 2031-02-08

F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.